In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...